New $45M liquid biopsy lab and diagnostic testing facility creates hundreds of new bioscience job opportunities in PhoenixContinue reading
Category Archives: AZBio News
BD Forms Sustainable Medical Technology Institute to Reduce the Environmental Impact of its Product Portfolio
Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company’s 2030+ environmental, social and governance (ESG) commitmentsContinue reading
Complementary Legal Resources for AZBio Members
In partnership with Arizona BioIndustry Association (AZBio), Booth Udall Fuller and Perkins Coie are offering weekly office hours to give AZBio members the opportunity to ask questions regarding the legal strategies of their businesses.
Flinn Foundation: Arizona’s bioscience sector hits record highs 20 years into strategic plan
The April 20 report, the latest performance analysis commissioned by the Phoenix-based Flinn Foundation and presented by TEConomy Partners, shows record highs in bioscience jobs, wages, venture capital, National Institutes of Health research funding, and university research and development.Continue reading
Aqualung Therapeutics Extends Global Reach With LeaderMed License Agreement
TUCSON, AZ / ACCESSWIRE / April 20, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the signing of a license agreement with the LeaderMed Health Group Limited (“LeaderMed”). The License Agreement provides LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the eNAMPT-neutralizing mAb, ALT-100 platform technology. The terms of the agreement have not been publicly disclosed but involve customary upfront fees, achievement milestones, and royalties that coincide with commercial sales.Continue reading
Flinn Foundation awards $1 million in grants to promote groundbreaking translational research
The first treatment for West Nile virus. A robotic device for children with cerebral palsy. A universal antivenom for snake bites. These goals emerge from three of the 10 translational research projects receiving funding from the Flinn Foundation in 2022 as part of a program to advance new products and services to improve patient care.Continue reading
Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium
TUCSON, Ariz., April 14, 2022 – Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its Critical Path for Sickle Cell Disease (CP-SCD) Consortium.Continue reading
University of Arizona Launches Incubator Outpost at Biosphere 2
TUCSON, Ariz.– The University of Arizona Center for Innovation (UACI) held a grand opening yesterday to celebrate its new startup incubator at Biosphere 2, which supports renewable energy and sustainable tech startups.
AlphaLogix announces market release of AlphaFlo® canine allograft
PHOENIX, March 31, 2022 /PRNewswire/ — Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo®. Equus Innovations is also the manufacturer of the highly successful RenoVō® equine allograft, distributed by Equine Amnio Solutions, LLC (EAS).
Avery Therapeutics, Inc Announces a Publication in Nature Scientific Reports Outlining Methods of Acquiring Cardiac MRI Endpoints in High Value Pre-Clinical Models of Heart Failure from University of Arizona Study
TUCSON, Ariz., – April 11, 2022 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company, today announced a publication in the peer-reviewed scientific journal, Nature Scientific Reports, outlining a novel technique in cardiac magnetic resonance imaging (CMR) data acquisition utilizing smart-signal gradient recalled echo (GRE)-based array sequences, entitled, “Free-breathing gradient recalled echo-based CMR in a swine heart failure model,” (Morris, el al. (2022). Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-07611-8).